New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CALM;BMY;PFE;CG;HLF;DUF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 23, 2014
16:17 EDTPFEPfizer announces new $11B share repurchase program
The board of directors also authorized a new $11B share repurchase program to be utilized over time. This new program is in addition to the $1.3B of authorization remaining under the company’s current share repurchase program.
15:39 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
08:15 EDTPFEPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
06:16 EDTCGPetSmart attracts interest from KKR, NY Post reports
Subscribe for More Information
October 22, 2014
13:37 EDTCGPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
12:55 EDTHLFPivotal analyst says Herbalife 'just not a pyramid scheme'
Pivotal Research analyst Tim Ramey said on CNBC that Herbalife "is just not a pyramid scheme."
October 21, 2014
18:33 EDTHLFIcahn reiterates view that high-yield market is a bubble
Says the Fed has given the economy, or the patient, "too much medicine." Says market should not be shorted. Again, says Apple (AAPL) CEO Tim is a "great CEO." Says Apple pay has a great future. Says Ebay (EBAY) is like his past campaign at Motorola. Reiterates view that Ebay should explore Paypal sale right now. Says Dell is on his radar screen. Says Warren Buffet sometimes too easy on companies, should do more on corporate governance. Again, says has never sold a share of Herbalife (HLF). Says Western Europe has "major problems," and continues to be short the Euro. Says energy stocks "getting cheap." Carl Icahn is speaking on Bloomberg TV.
07:15 EDTPFE, BMYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTPFEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
11:00 EDTHLFHerbalife volatility increases
Subscribe for More Information
08:48 EDTHLFHerbalife initiated with a Buy at Pivotal Research
Subscribe for More Information
07:47 EDTPFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTBMYIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
05:54 EDTHLFStocks with implied volatility movement; HLD SD
Stocks with implied volatility movement; Herbalife (HLF) 109, SandRidge Energy (SD) 97 according to iVolatility.
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use